What happens when you reach the highest dose of Mounjaro

What the SURMOUNT-1 data showed at 15mg

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. Participants on 15mg tirzepatide achieved an average weight reduction of around 20–21%, roughly double what the 5mg arm produced. That gap matters: the licensed schedule exists precisely because higher doses do more, on average, and the titration process is designed to get people to the highest dose they tolerate well.

What the data also showed is that weight loss is not linear. Most people lose weight fastest in the first six months, then the rate slows. By the time someone reaches 15mg (usually after at least five or six months of gradual increases) they are often already well into that slower phase. Reaching the maximum dose does not restart rapid loss; it tends to support continued progress at a steadier pace.

One thing the trial could not tell any individual is exactly where their plateau will be. Genetics, starting weight, diet, activity, and adherence all shape that. Your prescriber is better placed than any published average to discuss what realistic progress looks like for you specifically. If you want to understand the titration journey that leads to this point, the dose-increase process is covered in detail separately.

What changes (and what stays the same) at 15mg

Practically speaking, the pen and the injection routine are identical to every other dose in the range. The 15mg KwikPen delivers four weekly doses, refrigerated between 2–8°C, injected once a week into the abdomen, thigh or upper arm. When the pen arrives via DPD in plain, unbranded packaging, the tracking notification on your phone will look no different from the one that came with your first 2.5mg pen. The mechanism is the same too: tirzepatide continues to activate both GIP and GLP-1 receptors, slowing gastric emptying and signalling fullness.

What can change at higher doses is the side-effect profile. Gastrointestinal effects (nausea, loose stools, indigestion) tend to be most noticeable after a dose increase and then settle. At 15mg, some people find these more persistent than they were at lower doses; others who tolerated earlier steps well find 15mg equally manageable. The NHS patient information for tirzepatide sets out the full side-effect picture and explains which symptoms warrant prompt medical advice.

Clinical monitoring does not stop at the maximum dose. Repeat orders at nume receive a clinical review before every dispatch, a named prescriber assesses your progress and any concerns, not an automated system. If side effects at 15mg are limiting, the prescriber may recommend staying at 12.5mg instead; tolerability always takes priority over reaching the highest number on the scale. You can read more about how the earlier dose steps fit into the broader titration picture.

The 5% threshold and what NICE says about continuing treatment

NICE's TA1026 recommendation includes a straightforward stopping rule: if someone has lost less than 5% of their body weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. This applies whether that highest tolerated dose is 10mg, 12.5mg or 15mg. It is not a punishment clause, it is a recognition that a small proportion of people respond less well to tirzepatide, and that indefinite treatment without meaningful benefit is not in anyone's interest.

For people who do respond well, there is no automatic time limit on tirzepatide in the way that NICE's semaglutide recommendation (TA875) specifies a two-year maximum within specialist services. Tirzepatide is assessed on an ongoing basis. That said, what happens after sustained weight loss at 15mg is an active clinical question: the evidence on very long-term use, and on what happens if treatment stops, is still accumulating. If you are curious how people at the 7.5mg stage are getting on before reaching this point, the Mounjaro 7.5mg weight loss reviews on Trustpilot offer a useful picture of real-world experience. Your prescriber can discuss the current picture honestly.

Cost is a practical consideration at this stage too. Treatment at higher doses tends to be priced higher than starter doses, and the cost and access context for Mounjaro is worth understanding before you reach this point. The NICE 5% threshold is also a useful prompt to have an honest conversation with your prescriber about progress, which is exactly what the clinical review at each repeat order is designed to support.

What to do if you have questions at the highest dose

Reaching 15mg and wondering what comes next is a completely normal place to be. Some people want to know whether they can stay here indefinitely. Others are experiencing side effects for the first time and want guidance. A few are approaching the 5% threshold and need an honest conversation about their options. None of these situations call for guesswork, they call for a prescriber who knows your history.

At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is dispensed. That review is not a formality; it is the clinical checkpoint where questions like these actually get answered. If you are not yet on tirzepatide but are weighing it up, our weight-loss treatment overview covers the full landscape. If you have specific questions about missed doses or what happens with a dosing error, those are addressed on the missed-dose page, and you can also find out what happens if you accidentally take two doses of Mounjaro if that concern applies to you. And if you are ready to speak to someone, a free consultation with our prescribers is the right next step, the same-day review means you are not left waiting for answers.